CD47 and cancer: Human spleen cells are not accessible to directly evaluate extramedullary erythropoiesis in cancer patients receiving CD47-targeted therapeutics, but analysis of circulating erythroid precursors or liquid biopsy methods could be useful to detect induction of extramedullary erythropoiesis by these therapeutics.